IBDEI0N4 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11372,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,11373,0)
 ;;=156.9^^76^748^13
 ;;^UTILITY(U,$J,358.3,11373,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11373,1,1,0)
 ;;=1^156.9
 ;;^UTILITY(U,$J,358.3,11373,1,2,0)
 ;;=2^CHOLANGIOCARCINOMA
 ;;^UTILITY(U,$J,358.3,11373,2)
 ;;=^267102
 ;;^UTILITY(U,$J,358.3,11374,0)
 ;;=286.9^^76^748^14
 ;;^UTILITY(U,$J,358.3,11374,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11374,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,11374,1,2,0)
 ;;=2^COAGULATION DEFECTS
 ;;^UTILITY(U,$J,358.3,11374,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,11375,0)
 ;;=156.9^^76^748^17
 ;;^UTILITY(U,$J,358.3,11375,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11375,1,1,0)
 ;;=1^156.9
 ;;^UTILITY(U,$J,358.3,11375,1,2,0)
 ;;=2^GALLBLADDER CANCER
 ;;^UTILITY(U,$J,358.3,11375,2)
 ;;=^267102
 ;;^UTILITY(U,$J,358.3,11376,0)
 ;;=459.0^^76^748^19
 ;;^UTILITY(U,$J,358.3,11376,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11376,1,1,0)
 ;;=1^459.0
 ;;^UTILITY(U,$J,358.3,11376,1,2,0)
 ;;=2^HEMORRHAGE NOS
 ;;^UTILITY(U,$J,358.3,11376,2)
 ;;=^55877
 ;;^UTILITY(U,$J,358.3,11377,0)
 ;;=176.9^^76^748^20
 ;;^UTILITY(U,$J,358.3,11377,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11377,1,1,0)
 ;;=1^176.9
 ;;^UTILITY(U,$J,358.3,11377,1,2,0)
 ;;=2^KAPOSI'S SARCOMA, NOS
 ;;^UTILITY(U,$J,358.3,11377,2)
 ;;=^107993
 ;;^UTILITY(U,$J,358.3,11378,0)
 ;;=161.9^^76^748^21
 ;;^UTILITY(U,$J,358.3,11378,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11378,1,1,0)
 ;;=1^161.9
 ;;^UTILITY(U,$J,358.3,11378,1,2,0)
 ;;=2^LARYNGEAL CANCER
 ;;^UTILITY(U,$J,358.3,11378,2)
 ;;=^267128
 ;;^UTILITY(U,$J,358.3,11379,0)
 ;;=208.90^^76^748^22
 ;;^UTILITY(U,$J,358.3,11379,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11379,1,1,0)
 ;;=1^208.90
 ;;^UTILITY(U,$J,358.3,11379,1,2,0)
 ;;=2^LEUKEMIA,UNSP CELL TYPE
 ;;^UTILITY(U,$J,358.3,11379,2)
 ;;=^336874
 ;;^UTILITY(U,$J,358.3,11380,0)
 ;;=140.9^^76^748^23
 ;;^UTILITY(U,$J,358.3,11380,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11380,1,1,0)
 ;;=1^140.9
 ;;^UTILITY(U,$J,358.3,11380,1,2,0)
 ;;=2^LIP CANCER
 ;;^UTILITY(U,$J,358.3,11380,2)
 ;;=^266994
 ;;^UTILITY(U,$J,358.3,11381,0)
 ;;=155.0^^76^748^24
 ;;^UTILITY(U,$J,358.3,11381,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11381,1,1,0)
 ;;=1^155.0
 ;;^UTILITY(U,$J,358.3,11381,1,2,0)
 ;;=2^LIVER CANCER
 ;;^UTILITY(U,$J,358.3,11381,2)
 ;;=^73526
 ;;^UTILITY(U,$J,358.3,11382,0)
 ;;=200.60^^76^748^26
 ;;^UTILITY(U,$J,358.3,11382,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11382,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,11382,1,2,0)
 ;;=2^LYMPHOMA,ANAPLASTIC LARGE CELL
 ;;^UTILITY(U,$J,358.3,11382,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,11383,0)
 ;;=200.20^^76^748^27
 ;;^UTILITY(U,$J,358.3,11383,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11383,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,11383,1,2,0)
 ;;=2^LYMPHOMA,BURKITT'S
 ;;^UTILITY(U,$J,358.3,11383,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11384,0)
 ;;=201.90^^76^748^28
 ;;^UTILITY(U,$J,358.3,11384,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11384,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,11384,1,2,0)
 ;;=2^LYMPHOMA,HODGKIN'S
 ;;^UTILITY(U,$J,358.3,11384,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11385,0)
 ;;=200.70^^76^748^29
 ;;^UTILITY(U,$J,358.3,11385,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11385,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,11385,1,2,0)
 ;;=2^LYMPHOMA,LARGE CELL
 ;;^UTILITY(U,$J,358.3,11385,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,11386,0)
 ;;=200.40^^76^748^30
 ;;^UTILITY(U,$J,358.3,11386,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,11386,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,11386,1,2,0)
 ;;=2^LYMPHOMA,MANTLE CELL
